SIMENDAN Lacuna Pharma Pty Ltd

SIMENDAN (levosimendan) is proposed for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. ADHF is a life-threatening medical emergency where a patient's existing chronic heart failure worsens and the heart can no longer effectively pump blood to meet the body's needs, leading to severe fluid buildup and potential organ failure.